A randomized controlled safety trial of the diaphragm and cellulose sulfate microbicide gel in sexually active women in Zimbabwe

Contraception

Volumn 76, Issue 5, 2007, Pages 389-399

  van der Straten, Ariane ^a   Napierala, Sue ^a   Cheng, Helen ^a   Mauck, Christine ^b   Depineres, Teresa ^a   Dhlakama, Patricia ^c   Thompson, Marin ^a   Chipato, Tsungai ^c   Hammond, Nii ^c   Padian, Nancy ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF ZIMBABWE   (Zimbabwe)

Author keywords

Cervix; Diaphragm; Microbicide; Prevention of HIV STI; Safety trial; Vagina

Indexed keywords

CELLULOSE SULFATE; INJECTABLE CONTRACEPTIVE AGENT; LEVONORGESTREL; LUBRICATING AGENT; MICROBICIDE; PLACEBO;

ABDOMINAL PAIN; ABRASION; ADULT; ARTICLE; ASYMPTOMATIC BACTERIURIA; CHLAMYDIASIS; CLINICAL EXAMINATION; CLINICAL TRIAL; COLPOSCOPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG WITHDRAWAL; ECCHYMOSIS; EDEMA; ERYTHEMA; FEMALE; GEL; GENITAL ULCER; GRAM STAINING; HEMATURIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAUTERINE CONTRACEPTIVE DEVICE; LACERATION; MAJOR CLINICAL STUDY; MENORRHAGIA; NODULATION; ODOR; PATIENT COMPLIANCE; PATIENT SAFETY; PELVIS PAIN SYNDROME; PETECHIA; PREGNANCY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RASH; SEXUAL BEHAVIOR; SEXUAL INTERCOURSE; SIDE EFFECT; SURGICAL DRAINAGE; TRICHOMONIASIS; UNSPECIFIED SIDE EFFECT; URINALYSIS; URINARY TRACT INFECTION; URINARY URGENCY; UTERINE CERVICITIS; UTERINE CERVIX CAP; UTERUS BLEEDING; VAGINA BLEEDING; VAGINA CANDIDIASIS; VAGINA DISCHARGE; VAGINA FLORA; VAGINA PAIN; VAGINAL PRURITUS; VULVA PRURITUS; VULVITIS; ZIMBABWE;

ADMINISTRATION, INTRAVAGINAL; ADOLESCENT; ADULT; ANTI-INFECTIVE AGENTS; CELLULOSE; CONTRACEPTIVE DEVICES, FEMALE; FEMALE; GENITAL DISEASES, FEMALE; HUMANS; MIDDLE AGED; PREGNANCY; SEXUALLY TRANSMITTED DISEASES; VAGINA; ZIMBABWE;

EID: 35349019753     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.contraception.2007.07.004     Document Type: Article

References (27)

1. WHO. HIV/AIDS Epidemiological Surveillance Report for the WHO African Region: 2005 Update (2005), WHO, Harare
2. UNAIDS. Evidence for HIV decline in Zimbabwe (2005), UNAIDS, Geneva
3. Pettifor A.E., Measham D.M., Rees H.V., and Padian N.S. Sexual power and HIV risk South Africa. Emerg Infect Dis 10 (2004) 1996-2004
4. Susser I., and Stein Z. Culture, sexuality, and women's agency in the prevention of HIV/AIDS in southern Africa. Am J Public Health 90 (2000) 1042-1048
5. Weiss E., Whelan D., and Gupta G. Vulnerability and opportunity: adolescents and HIV/AIDS in the developing world (1996), International Center for Research on Women, Washington, DC
6. Anderson R.A., Feathergill K., Diao X.H., et al. Contraception by Ushercell™ (cellulose sulfate) in formulation: duration of effect and dose effectiveness. Contraception 70 (2004) 415-422
7. Anderson R.A., Feathergill K.A., Diao X.H., et al. Preclinical evaluation of sodium cellulose sulfate (Ushercell) as a contraceptive antimicrobial agent. J Androl 23 (2002) 426-438
8. El-Sadr W.M., Mayer K.H., Maslankowski L., et al. Safety and acceptability of cellulose sulfate as a vaginal microbicide in HIV-infected women. AIDS 20 (2006) 1109-1116
9. Schwartz J.L., Mauck C., Lai J.J., et al. Fourteen-day safety and acceptability study of 6% cellulose sulfate gel: a randomized double-blind Phase I safety study. Contraception 74 (2006) 133-140
10. Mauck C., Frezieres R., Walsh T., Robergeau K., and Callahan M. Cellulose sulfate: tolerance and acceptability of penile application. Contraception 64 (2001) 377-381
11. CONRAD. Phase III trials of Cellulose sulfate microbicide for HIV prevention closed: press release. Jan. 31, 2007. http://www.conrad.org/press/phaseIIItrials.htm [accessed July 6, 2007]
12. Moench T., Chipato T., and Padian N. Preventing disease by protecting the cervix: the unexplored promise of internal vaginal barrier devices. AIDS 15 (2001) 1595-1602
13. Jacobson D.L., Peralta L., Graham N.M., and Zenilman J. Histologic development of cervical ectopy: relationship to reproductive hormones. Sex Transm Dis 27 (2000) 252-258
14. Patterson B.K., Landay A., Andersson J., et al. Repertoire of chemokine receptor expression in the female genital tract: implications for human immunodeficiency virus transmission. Am J Pathol 153 (1998) 481-490
15. Pudney J., Quayle A.J., and Anderson D.J. Immunological microenvironments in the human vagina and cervix: mediators of cellular immunity are concentrated in the cervical transformation zone. Biol Reprod 73 (2005) 1253-1263
16. Zhang L., He T., Talal A., Wang G., Frankel S.S., and Ho D.D. In vivo distribution of the human immunodeficiency virus/simian immunodeficiency virus coreceptors: CXCR4, CCR3, and CCR5. J Virol 72 (1998) 5035-5045
17. Matthews J. Clinical trials examining cervical barriers as potential methods for prevention of HIV and other sexually transmitted infections. Microbic Quart 4 (2006) 7-11
18. Gupta K., Hillier S.L., Hooton T.M., Roberts P.L., and Stamm W.E. Effects of contraceptive method on the vaginal microbial flora: a prospective evaluation. J Infect Dis 181 (2000) 595-601
19. Hooton T.M., Roberts P.L., and Stamm W.E. Effects of recent sexual activity and use of a diaphragm on the vaginal microflora. Clin Infect Dis 19 (1994) 274-278
20. Trussell J. The essentials of contraception: efficacy, safety, and personal considerations. In: Hatcher R.A., Trussell J., Stewart F., et al. (Eds). Contraceptive technology. 18th revised ed. (2004), Ardent Media, New York 221-252
21. Pretorius E.S., Timbers K., Malamud D., and Barnhart K. Magnetic resonance imaging to determine the distribution of a vaginal gel: before, during, and after both simulated and real intercourse. Contraception 66 (2002) 443-451
22. CONRAD, and WHO. Manual for the Standardization of Colposcopy for Evaluation of Vaginal Products (2004), CONRAD, Arlington (Va)
23. Nugent R.P., Krohn M.A., and Hillier S.L. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of Gram stain interpretation. J Clin Microbiol 29 (1991) 297-301
24. Amsel R., Totten P.A., Spiegel C.A., Chen K.C., Eschenbach D., and Holmes K.K. Nonspecific vaginitis. Diagnostic criteria and microbial and epidemiologic associations. Am J Med 74 (1983) 14-22
25. Barnhart K.T., Rosenberg M.J., MacKay H.T., et al. Contraceptive efficacy and safety of a novel spermicidal microbicide used with a diaphragm. Obstet Gynecol 110 3 (2007) 577-586
26. Van Damme L., Ramjee G., Alary M., et al. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet 360 (2002) 971-977
27. Simoes J.A., Citron D.M., Aroutcheva A., et al. Two novel vaginal microbicides (polystyrene sulfonate and cellulose sulfate) inhibit Gardnerella vaginalis and anaerobes commonly associated with bacterial vaginosis. Antimicrob Agents Chemother 46 (2002) 2692-2695